No abstract available.
Dementia* ; Humans ; Urinary Incontinence*

The metal ceramic crown is currently the most popular complete veneer restoration in dentistry, but in many cases, the metal cervical collar at the facial margin is unesthetic and unacceptable. Facial porcelain margin has been used in place of it. But this dose not solve the problems, such as dark gingival discoloration and cervical opaque reflection of porcelain veneer. Recently, metal copings which were designed to terminate its labio-cervical end on the axial walls coronal to the shoulder have been clinically used to solve the esthetic problem of metal ceramic crown. But in this design, porcelain veneer of labio-cervical area which is not supported by metal may not be able to resist the stress during cementation and mastication. The purpose of this study was to evaluate fracture strength and fractured appearance of crowns according to different coping designs. A resin maxillary left central incisor analogue was prepared for a metal ceramic crown, and metal dies were made with duplication mold. Metal copings were made and assigned to one of four groups based on facial framework designs: group 1, coping with 0.5mm metal collar; group 2, metal extended to the shoulder; group 3, metal extended to 1 mm coronal to the shoulder; group 4, metal extended to 2mm coronal to the shoulder. Copings and crowns were adjusted to be same size and thickness, and cemented to metal dies with zinc phosphate cement by finger pressure. Fracture strength was measured with Instron Universal Testing Machine. Metaldies were anchored in Three-way-vice at 3mm below finish line and at 130degree inclined to the lone axis of the crown. Load was directed lingually at 2mm below midincisal edge. Load value at initial crack and at catastrophic fracture was recorded. The results obtained were as follows: 1. Fracture strength values at initial crack were higher in groups 1, 2 than in groups 3, 4 but this difference was not statistically significant(P<0.05). 2. Conventional metal collared crown had greater catastrophic fracture strength than any other collarless crowns. 3. The greater the labial metal coping reduction, the lower the catastrophic fracture strength of crowns but when more than 1mm of labial metal reduction was done, the difference in strengths was not statistically significant(p<0.05). 4. The strongest collarless coping design was group 2.
Axis, Cervical Vertebra ; Cementation ; Ceramics* ; Crowns* ; Dental Porcelain ; Dentistry ; Fingers ; Fungi ; Incisor ; Mastication ; Shoulder ; Zinc Phosphate Cement

No abstract available.
Sinusitis*

PURPOSE: To evaluate the effectiveness of 0.1% topical bromfenac as an adjunctive treatment with intravitreal bevacizumab (IVB) injection for branch retinal vein occlusion (BRVO) patients.METHODS: We retrospectively evaluated 68 eyes of 68 patients with macular edema (ME) secondary to BRVO who were treated with IVB injection and followed up for at least 12 months. Of the 68 eyes, 38 were treated with IVB combined with 0.1% topical bromfenac and 30 were treated with IVB alone. IVB reinjection was performed in cases of recurrence. The primary outcome measurement was the number of IVB injections. Changes in the best-corrected visual acuity (BCVA) and central foveal thickness (CFT) during the 12-month follow-up were compared.RESULTS: There was no significant difference in the BCVA or CFT between the two groups at the initial and final examinations. However, the number of IVB injections was significantly lower in the 0.1% bromfenac-treated eyes (p < 0.01) than in the control eyes (4.1 ± 0.7 vs. 5.0 ± 0.6 times).CONCLUSIONS: Compared to IVB monotherapy, topical bromfenac as an adjunctive treatment with IVB injection of eyes with ME secondary to BRVO did not affect visual outcomes, but it reduced the number of IVB injections.
Bevacizumab ; Follow-Up Studies ; Humans ; Macular Edema ; Recurrence ; Retinal Vein Occlusion ; Retinal Vein ; Retinaldehyde ; Retrospective Studies ; Visual Acuity

No abstract available.
Hand Deformities ; Humans ; Parkinsonian Disorders*

Intra-articular hyaluronic acid injections for symptomatic treatment of osteoarthritis are widely used but can result in complications, such as infectious arthritis. Staphylococcus lugdunensis is a common normal skin flora but can cause severe infectious disease, such as infective endocarditis. We present the first report of infectious arthritis caused by methicillin-sensitive S. lugdunensis after intra-articular hyaluronic acid injection in an immunocompromised patient in Korea.
Arthritis, Infectious* ; Arthritis, Rheumatoid* ; Communicable Diseases ; Diabetes Mellitus* ; Endocarditis ; Humans ; Hyaluronic Acid* ; Immunocompromised Host ; Korea ; Osteoarthritis ; Skin ; Staphylococcus lugdunensis* ; Staphylococcus*

Exogenous glucocorticoid has anti-inflammatory effect to reduce symptoms and signs of rheumatoid arthritis. However there are few reports about the role of endogenous glucocorticoid in rheumatoid arthritis. Recently we experienced a case of rheumatoid arthritis developed in a female patient with Cushing's disease as her cortisol level decreased during medical management of hypercortisolemia. She underwent trans-sphenoidal surgery for Cushing's disease (pituitary microadenoma). Six years after surgery she had disease recurrence and received brain radiotherapy and ketoconazole medication. Four years later she developed seronegative rheumatoid arthritis. 24 hour urine cortisol level was below the normal value at that time. Polyarthralgia improved with prednisolone (5mg/day). But polyarthralgia was aggravated as cortisol level decreased below the normal value after prednisolone was discontinued. This case and previous reports suggest that the development and aggravation of rheumatoid arthritis is associated with relative cortisol deficiency, or alteration of balance between neuroendocrine system(hypothalamic- pituitary-adrenal axis) and inflammatory process.
Arthralgia ; Arthritis, Rheumatoid* ; Brain ; Female ; Humans ; Hydrocortisone ; Ketoconazole ; Prednisolone ; Radiotherapy ; Recurrence ; Reference Values

Systemic lupus erythematosus (SLE) has been described very rarely in association with underlying malignancy. We experienced a 68-year-old male with systemic erythematosus lupus associated with squamous cell lung cancer. He had radiation therapy as a primary treatment modality. Ten months after the radiation therapy, he suffered from intermittent fever, myalgia, multiple arthralgia, dry cough, and dyspnea. He had leukocytosis and lymphopenia. Anti-nuclear antibody was positive. He had bilateral pleural effusion, pericardial effusion, and proteinuria (2405 mg/day). He had peripheral neuropathy with lower extremity weakness. There was no evidence of recurrence of lung cancer. He was treated with naproxen (1 gm/day) with symptomatic improvement. We describe a clinical course of paraneoplastic SLE in patient with lung cancer, and review the literatures.
Aged ; Arthralgia ; Cough ; Dyspnea ; Fever ; Humans ; Leukocytosis ; Lower Extremity ; Lung Neoplasms* ; Lung* ; Lupus Erythematosus, Systemic ; Lymphopenia ; Male ; Myalgia ; Naproxen ; Paraneoplastic Syndromes* ; Pericardial Effusion ; Peripheral Nervous System Diseases ; Pleural Effusion ; Proteinuria ; Recurrence

BACKGROUND: The angiotensin-converting enzyme inhibitors have been found to be safe and efficacious in the treatment of essential hypertension. Fosinopril is the first angiotensin-converting enzyme inhibitor from a new class of agents containing phosphorus. This drug is known to be metabolized to almost and equal extent by the hepatic and renal pathways. METHODS: This study was performed to investigate the efficacy and safety of oral fosinopril, a new class of phosporus-containing angiotensin converting enzyme inhibitor, on essential hypertension. A single daily dose of 10mg to 20mg fosinopril was administered in 21 hypertensive patients with diastolic blood pressure in the range of 95mmHg-115mmHg while off all other anti-hypertensive agents for 10 weeks. Blood pressure and heart rate were measured every 4 weeks. The complete blood count, blood chemistry by SMA-12, serum electrolytes and urinalysis were performed at 12th week of therapy. RESULTS: 1) Baseline systolic and diastolic blood pressures after 2 weeks of placebo at sitting position were 158.8+/-15.7 and 99.4+/-6.3mmHg respectively. There was a statistcally significant reduction of blood pressure after 4 week treatment of fosinopril which was maintained up to 12 weeks of follow-up(158.8+/-15.7-99.4+/-6.3mmHg vs 139.3+/-18.2/86.6+/-10.3mmHg, p<0.05). 2) The proportion of responders defined by diastolic blood pressures less than 90mmHg or decline more than 10mmHg at 4, 8 and 12 weeks after treatment with fosinopril were 90.5, 95.2, and 95.2% respectively. 3) THere were no significant changes in blood chemistry, serum electrolytes, hematologic findings and heart rate over the treatment period. 4) Three patients experienced severe non-productive cough that required to discontinue the medication. CONCLUSION: In patients with mild to moderate hypertension, once-daily fosinopril(10mg and 20mg) provided significant anti-hypertensive effects without serious side effects. The 10mg dose was effective in majority of patients and may be considered as a starting dose.
Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Blood Cell Count ; Blood Pressure ; Chemistry ; Cough ; Electrolytes ; Fosinopril* ; Heart Rate ; Humans ; Hypertension ; Peptidyl-Dipeptidase A ; Phosphorus ; Urinalysis

PURPOSE: Intravenous propofol anesthesia has been safely and effectively used in the ureteroscopic management of lower ureteral calculi. We investigated whether we can also use propofol anesthesia effectively for the treatment of middle and upper ureteral calculi. MATERIALS AND METHODS: We performed ureteroscopy with intravenous propofol anesthesia in 200 consecutive patients with ureteral calculi from July 1998 to December 2001. We divided them into 2 groups. Group 1 consisted of 59 patients, 48 men and 11 women, with upper and midureteral calculi, and group 2 consisted of 141 patients, 94 men and 47 women, with lower ureteral calculi. We compared safety, success rate, length of hospital stay and complication rate between the two groups. RESULTS: The overall success rate for ureteroscopy was 94.5% (189/200). Seven patients suffered perioperative complications, none of whom needed to change mode of anesthesia or remembered discomfort during the operation. In group 1, stone size, operation time and postoperative hospital stays were 7.5+/-3.2mm, 33.0+/-20.3 minutes and 1.9+/-1.0 days, respectively. The equivalent results were 6.2+/-2.9mm, 22.9+/-15.0 minutes and 1.4+/-0.9 days, respectively, in group 2. There were no significant differences in age, complication rate or success rate between the two groups. CONCLUSIONS: In patients with middle and upper ureteral calculi, ureteroscopic stone removal under intravenous propofol anesthesia can be performed safely and effectively without any significant increase in morbidity or patient discomfort.
Anesthesia* ; Calculi ; Female ; Humans ; Length of Stay ; Male ; Propofol* ; Ureter* ; Ureteral Calculi* ; Ureteroscopy*